Shanghai HeartCare Medical IPO: Valuation Insights
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.
594 Views
Heartcare (心玮医疗) IPO: Decent Upside Barring Negative Lawsuit Outcomes
We provide an update for HeartCare's book building. We think the upside is substantial barring negative outcomes from the legal proceedings with...
325 Views
Acotec (先瑞达) Pre-IPO: Thoughts on Valuation
We provide our forecast and valuation for the company's two key products AcoArt Orchid & Dhalia, as well as AcoArt Tulip & Litos.
225 Views
Shanghai HeartCare (心玮医疗) Pre-IPO: Thoughts on Valuation
We forecast the sales of HeartCare's four key products, namely Captor, Intracranial Catheter, LAA Occluder, and embolic coil, and also provide an...
410 Views
ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
446 Views